3-(5-fluoro-pyridin-3-yl)-3-oxopropionitrile | 1205532-07-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(5-fluoro-pyridin-3-yl)-3-oxopropionitrile
• 英文别名: 3-(5-Fluoropyridin-3-yl)-3-oxopropanenitrile
• CAS: 1205532-07-5
• 化学式: C₈H₅FN₂O
• 分子量: 164.139
• InChiKey: LISJVSVCOUWLQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  53.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(5-fluoro-pyridin-3-yl)-3-oxopropionitrile 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以1.3 g的产率得到5-(5-fluoro-pyridin-3-yl)-2H-pyrazol-3-ylamine
  参考文献：
  名称：

  N-[5-(5-Fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A Medicinal Chemistry Effort toward an α7 Nicotinic Acetylcholine Receptor Agonist Preclinical Candidate

  摘要：

  alpha 7 nicotinic acetylcholine receptors (alpha 7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment, associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY 361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the alpha 7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.

  DOI：

  10.1021/jm3013568
• 作为产物：
  描述：

  5-氟烟酸 在 正丁基锂 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 2.0h， 生成 3-(5-fluoro-pyridin-3-yl)-3-oxopropionitrile
  参考文献：
  名称：

  N-[5-(5-Fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A Medicinal Chemistry Effort toward an α7 Nicotinic Acetylcholine Receptor Agonist Preclinical Candidate

  摘要：

  alpha 7 nicotinic acetylcholine receptors (alpha 7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment, associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY 361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the alpha 7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.

  DOI：

  10.1021/jm3013568

文献信息

• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
  申请人：Bothmann Hendrick

  公开号：US20100130474A1

  公开（公告）日：2010-05-27

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法以及使用它们调节α7尼古丁乙酰胆碱受体和/或治疗各种疾病、疾病和情况的方法。所提供的化合物可以影响神经系统、精神病和/或炎症系统等方面。
• <i>N</i>-[5-(5-Fluoropyridin-3-yl)-1<i>H</i>-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A Medicinal Chemistry Effort toward an α7 Nicotinic Acetylcholine Receptor Agonist Preclinical Candidate
  作者：Riccardo Zanaletti、Laura Bettinetti、Cristiana Castaldo、Ilaria Ceccarelli、Giuseppe Cocconcelli、Thomas A. Comery、John Dunlop、Eva Genesio、Chiara Ghiron、Simon N. Haydar、Flora Jow、Laura Maccari、Iolanda Micco、Arianna Nencini、Carmela Pratelli、Carla Scali、Elisa Turlizzi、Michela Valacchi

  DOI：10.1021/jm3013568

  日期：2012.11.26

  alpha 7 nicotinic acetylcholine receptors (alpha 7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment, associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY 361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the alpha 7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.